United Therapeutics Corp
NASDAQ:UTHR

Watchlist Manager
United Therapeutics Corp Logo
United Therapeutics Corp
NASDAQ:UTHR
Watchlist
Price: 359.58 USD -0.16% Market Closed
Market Cap: 16.1B USD
Have any thoughts about
United Therapeutics Corp?
Write Note

Wall Street
Price Targets

UTHR Price Targets Summary
United Therapeutics Corp

Wall Street analysts forecast UTHR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for UTHR is 401.61 USD with a low forecast of 305.02 USD and a high forecast of 630 USD.

Lowest
Price Target
305.02 USD
15% Downside
Average
Price Target
401.61 USD
12% Upside
Highest
Price Target
630 USD
75% Upside

UTHR Last Price Targets
United Therapeutics Corp

The latest public price target was made on Oct 31, 2024 by Jasper Hellweg from Argus Research , who expects UTHR stock to rise by 11% over the next 12 months. You can read more about this price target by viewing the article on TheFly.

Analyst Price Target Date Article
Jasper Hellweg
Argus Research
400 USD
Upside 11%
1 month ago
Oct 31, 2024
United Therapeutics price target raised to $400 from $360 at Argus
TheFly
Andrew Fein
H.C. Wainwright
425 USD
Upside 18%
1 month ago
Oct 31, 2024
United Therapeutics Corp. (UTHR) PT Raised to $425 at H.C. Wainwright
StreetInsider
Eun Yang
Jefferies
432 USD
Upside 20%
3 months ago
Sep 23, 2024
United Therapeutics Corp. (UTHR) PT Raised to $432 at Jefferies
StreetInsider
Hartaj Singh
Oppenheimer
575 USD
Upside 60%
3 months ago
Aug 28, 2024
United Therapeutics Corp. (UTHR) PT Raised to $575 at Oppenheimer
StreetInsider
Ashwani Verma
UBS
370 USD
Upside 3%
5 months ago
Jul 8, 2024
United Therapeutics Corp. (UTHR) PT Raised to $370 at UBS
StreetInsider
Tiago Fauth
Wells Fargo
350 USD
Downside 3%
6 months ago
Jun 12, 2024
United Therapeutics price target raised to $350 from $325 at Wells Fargo
TheFly
Hartaj Singh
Oppenheimer
400 USD
Upside 11%
7 months ago
May 2, 2024
United Therapeutics price target raised to $400 from $375 at Oppenheimer
TheFly
Chris Shibutani
Goldman Sachs
215 USD
Downside 40%
10 months ago
Feb 12, 2024
This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate
Benzinga
Show More Price Targets
Show Less Price Targets
Jasper Hellweg
Argus Research
Price Target 400 USD
Upside/Downside 11%
View Source
Andrew Fein
H.C. Wainwright
Price Target 425 USD
Upside/Downside 18%
View Source
Eun Yang
Jefferies
Price Target 432 USD
Upside/Downside 20%
View Source
Hartaj Singh
Oppenheimer
Price Target 575 USD
Upside/Downside 60%
View Source
Ashwani Verma
UBS
Price Target 370 USD
Upside/Downside 3%
View Source
Tiago Fauth
Wells Fargo
Price Target 350 USD
Upside/Downside 3%
View Source
Hartaj Singh
Oppenheimer
Price Target 400 USD
Upside/Downside 11%
View Source
Chris Shibutani
Goldman Sachs
Price Target 215 USD
Upside/Downside 40%
View Source
Show More Price Targets
Show Less Price Targets
United Therapeutics Corp Competitors:
Price Targets
0HS8
Caladrius Biosciences Inc
456% Upside
VCEL
Vericel Corp
9% Upside
251120
Bio-FD&C Co Ltd
50% Upside
HPHA
Heidelberg Pharma AG
408% Upside
ACAD
ACADIA Pharmaceuticals Inc
52% Upside
XOMA
XOMA Corp
235% Upside
MYGN
Myriad Genetics Inc
77% Upside
NVAX
Novavax Inc
104% Upside

Revenue
Forecast

Revenue Estimate
United Therapeutics Corp

For the last 8 years the compound annual growth rate for United Therapeutics Corp's revenue is 6%. The projected CAGR for the next 4 years is 13%.

6%
Past Growth
13%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
United Therapeutics Corp

For the last 8 years the compound annual growth rate for United Therapeutics Corp's operating income is 7%. The projected CAGR for the next 4 years is 12%.

7%
Past Growth
12%
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

Net Income Estimate
United Therapeutics Corp

For the last 8 years the compound annual growth rate for United Therapeutics Corp's net income is 5%. The projected CAGR for the next 4 years is 10%.

5%
Past Growth
10%
Estimated Growth
Estimates Accuracy
-8%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is UTHR's stock price target?
Price Target
401.61 USD

According to Wall Street analysts, the average 1-year price target for UTHR is 401.61 USD with a low forecast of 305.02 USD and a high forecast of 630 USD.

What is United Therapeutics Corp's Revenue forecast?
Projected CAGR
13%

For the last 8 years the compound annual growth rate for United Therapeutics Corp's revenue is 6%. The projected CAGR for the next 4 years is 13%.

What is United Therapeutics Corp's Operating Income forecast?
Projected CAGR
12%

For the last 8 years the compound annual growth rate for United Therapeutics Corp's operating income is 7%. The projected CAGR for the next 4 years is 12%.

What is United Therapeutics Corp's Net Income forecast?
Projected CAGR
10%

For the last 8 years the compound annual growth rate for United Therapeutics Corp's net income is 5%. The projected CAGR for the next 4 years is 10%.

Back to Top